GPCR Inhibition in Treating Lymphoma

Overview

Journal ACS Med Chem Lett

Publisher American Chemical Society

Specialty Chemistry

Date 2024 Jan 19

PMID 38239337

Authors

Marilia Barreca

Virginia Spano

Maria V Raimondi

Roberta Bivacqua

Stefano Giuffrida

Alessandra Montalbano

Andrea Cavalli

Francesco Bertoni

Paola Barraja

Affiliations

Soon will be listed here.

Abstract

G protein-coupled receptors (GPCRs) are important classes of cell surface receptors involved in multiple physiological functions. Aberrant expression, upregulation, and mutation of GPCR signaling pathways are frequent in many types of cancers, promoting hyperproliferation, angiogenesis, and metastasis. Recent studies showed that alterations of GPCRs are involved in different lymphoma types. Herein, we review the synthetic strategies to obtain GPCR inhibitors, focusing on CXCR4 inhibitors which represent most of the GPCR inhibitors available in the market or under preclinical investigations for these diseases.

Citing Articles

The G Protein-Coupled Estrogen Receptor (GPER): A Critical Therapeutic Target for Cancer.

Hall K, Filardo E Cells. 2023; 12(20).

PMID: 37887304 PMC: 10605794. DOI: 10.3390/cells12202460.

Identification of pyrrolo[3',4':3,4]cyclohepta[1,2-d][1,2]oxazoles as promising new candidates for the treatment of lymphomas.

Barreca M, Spano V, Rocca R, Bivacqua R, Gualtieri G, Raimondi M Eur J Med Chem. 2023; 254:115372.

PMID: 37068384 PMC: 10287037. DOI: 10.1016/j.ejmech.2023.115372.

Synthetic Analogs of Marine Alkaloid Aplysinopsin Suppress Anti-Apoptotic Protein BCL2 in Prostate Cancer.

El-Sawy E, El-Shahid Z, Soliman A, Nassrallah A, Abdelwahab A, Kirsch G Molecules. 2023; 28(1).

PMID: 36615305 PMC: 9821956. DOI: 10.3390/molecules28010109.

Design, Synthesis, Molecular Modeling, and Anticancer Evaluation of New VEGFR-2 Inhibitors Based on the Indolin-2-One Scaffold.

Abdelgawad M, Hayallah A, Bukhari S, Musa A, Elmowafy M, Abdel-Rahman H Pharmaceuticals (Basel). 2022; 15(11).

PMID: 36422546 PMC: 9698773. DOI: 10.3390/ph15111416.

New tricyclic systems as photosensitizers towards triple negative breast cancer cells.

Barreca M, Ingarra A, Raimondi M, Spano V, Palumbo Piccionello A, De Franco M Arch Pharm Res. 2022; 45(11):806-821.

PMID: 36399284 PMC: 9701179. DOI: 10.1007/s12272-022-01414-1.

References

Chen L, Ouyang J, Wienand K, Bojarczuk K, Hao Y, Chapuy B . CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. Haematologica. 2019; 105(5):1361-1368. PMC: 7193488. DOI: 10.3324/haematol.2019.216218. View

Burger J, Kipps T . CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2005; 107(5):1761-7. DOI: 10.1182/blood-2005-08-3182. View

Rosenkilde M, Gerlach L, Hatse S, Skerlj R, Schols D, Bridger G . Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J Biol Chem. 2007; 282(37):27354-27365. DOI: 10.1074/jbc.M704739200. View

Ros-Blanco L, Anido J, Bosser R, Este J, Clotet B, Kosoy A . Noncyclam tetraamines inhibit CXC chemokine receptor type 4 and target glioma-initiating cells. J Med Chem. 2012; 55(17):7560-70. DOI: 10.1021/jm300862u. View

Pansy K, Feichtinger J, Ehall B, Uhl B, Sedej M, Roula D . The -Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro. Int J Mol Sci. 2019; 20(19). PMC: 6801866. DOI: 10.3390/ijms20194740. View

Debnath B, Xu S, Grande F, Garofalo A, Neamati N . Small molecule inhibitors of CXCR4. Theranostics. 2013; 3(1):47-75. PMC: 3563081. DOI: 10.7150/thno.5376. View

Covic L, Gresser A, Talavera J, Swift S, Kuliopulos A . Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci U S A. 2002; 99(2):643-8. PMC: 117359. DOI: 10.1073/pnas.022460899. View

Recasens-Zorzo C, Cardesa-Salzmann T, Petazzi P, Ros-Blanco L, Esteve-Arenys A, Clot G . Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. Haematologica. 2018; 104(4):778-788. PMC: 6442946. DOI: 10.3324/haematol.2017.180505. View

Gerlach L, Skerlj R, Bridger G, Schwartz T . Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem. 2001; 276(17):14153-60. DOI: 10.1074/jbc.M010429200. View

10.

Peng S, Zhang X, Paul D, Kays L, Gough W, Stewart J . Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol Cancer Ther. 2014; 14(2):480-90. DOI: 10.1158/1535-7163.MCT-14-0850. View

11.

Bodart V, Anastassov V, Darkes M, Idzan S, Labrecque J, Lau G . Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4. Biochem Pharmacol. 2009; 78(8):993-1000. DOI: 10.1016/j.bcp.2009.06.010. View

12.

Tarantelli C, Gaudio E, Arribas A, Kwee I, Hillmann P, Rinaldi A . PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. Clin Cancer Res. 2017; 24(1):120-129. DOI: 10.1158/1078-0432.CCR-17-1041. View

13.

Yang D, Zhou Q, Labroska V, Qin S, Darbalaei S, Wu Y . G protein-coupled receptors: structure- and function-based drug discovery. Signal Transduct Target Ther. 2021; 6(1):7. PMC: 7790836. DOI: 10.1038/s41392-020-00435-w. View

14.

Adlere I, Caspar B, Arimont M, Dekkers S, Visser K, Stuijt J . Modulators of CXCR4 and CXCR7/ACKR3 Function. Mol Pharmacol. 2019; 96(6):737-752. DOI: 10.1124/mol.119.117663. View

15.

Reinholdt L, Laursen M, Schmitz A, Bodker J, Jakobsen L, Bogsted M . The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines. Biomark Res. 2016; 4:12. PMC: 4908729. DOI: 10.1186/s40364-016-0067-2. View

16.

Nugent A, Proia R . The role of G protein-coupled receptors in lymphoid malignancies. Cell Signal. 2017; 39:95-107. PMC: 5600616. DOI: 10.1016/j.cellsig.2017.08.002. View

17.

Beider K, Ribakovsky E, Abraham M, Wald H, Weiss L, Rosenberg E . Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140. Clin Cancer Res. 2013; 19(13):3495-507. DOI: 10.1158/1078-0432.CCR-12-3015. View

18.

Peled A, Abraham M, Avivi I, Rowe J, Beider K, Wald H . The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res. 2013; 20(2):469-79. DOI: 10.1158/1078-0432.CCR-13-1302. View

19.

Lee Y, Basith S, Choi S . Recent Advances in Structure-Based Drug Design Targeting Class A G Protein-Coupled Receptors Utilizing Crystal Structures and Computational Simulations. J Med Chem. 2017; 61(1):1-46. DOI: 10.1021/acs.jmedchem.6b01453. View

20.

Batur G, Ermert P, Zimmermann J, Obrecht D . Macrocycle Therapeutics to Treat Life-threatening Diseases. Chimia (Aarau). 2021; 75(6):508-513. DOI: 10.2533/chimia.2021.508. View